Skip to main content

Bio-Rad to Host Investor Day on February 25

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today that it will host an in-person investor day in New York City on Friday, February 25, 2022, at 10:30 a.m. EST. A live webcast will also be available. Registration is required to attend the event.

The event will feature presentations from Norman Schwartz, Chief Executive Officer, and other key members of Bio-Rad’s executive leadership team. Members of the leadership team will also participate in a Q&A session following the presentations.

Webcast Details

A link to the event and registration will be available on the “Investor Relations” section of our website under “Events & Conferences” at For those who cannot participate at the scheduled time, a replay of the event, along with accompanying presentation slides, will be archived on the website for up to a year following its conclusion.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit


Investor Contact:

Bio-Rad Laboratories, Inc.

Edward Chung, Vice President, Investor Relations


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.